October 10, 2024 Meeting of the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) @US

U.S. Food and Drug Administration | October 10, 2024 Meeting of the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) @US_FDA | Uploaded 18 hours ago | Updated 2 hours ago
The Committee will discuss new drug application (NDA) 215244, for elamipretide hydrochloride injection, submitted by Stealth BioTherapeutics Inc., for the treatment of Barth Syndrome.

What is FDA’s role in regulating drugs? (30 seconds)

Electronic Drug Registration and Listing (eDRLS) Using CDER Direct – 2024 – Part 1

Advancing Generic Drug Development: Translating Science to Approval 2024 (Day 1)

Episode 5 - On The Road with Jim Jones - April 2024

What does the FDA do after drugs are approved? (30 seconds)

Module 7 – Case Study 7: QSP Modeling to Predict Safety & Efficacy

Regulatory Education for Industry (REdI) Annual Conference 2024: Day 2 – Session 3

FDA D.I.S.C.O. Burst Edition: FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-posit...